Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NMT1 | P30419 | 3/20 | 0.40 |
| ▸ | NMT2 | O60551 | 2/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1486564 | 1.00 | MAPT (0.41) | MAPTTP53SMN1; SMN2NMT1NMT2 | |
| SCHEMBL1486617 | 0.94 | BCL2 (0.38) | MAPTBACE1 | |
| SCHEMBL1486614 | 0.94 | BCL2 (0.38) | MAPTBACE1 | |
| SCHEMBL1962206 | 0.88 | MAPT (0.40) | MAPTBACE1 | |
| SCHEMBL1486511 | 0.87 | NMT1 (0.44) | MAPTTP53SMN1; SMN2NMT1NMT2 | |
| SCHEMBL2507712 | 0.85 | CHRM2 (0.48) | MAPTALDH1A1LMNAHPGD | |
| SCHEMBL2507709 | 0.85 | CHRM2 (0.48) | MAPTALDH1A1LMNAHPGD | |
| SCHEMBL1486588 | 0.85 | MAPT (0.46) | MAPTTP53SMN1; SMN2NMT1NMT2 | |
| SCHEMBL1486586 | 0.85 | MAPT (0.46) | MAPTTP53SMN1; SMN2NMT1NMT2 | |
| SCHEMBL1486503 | 0.84 | MAPT (0.43) | MAPTTP53SMN1; SMN2NMT1NMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263594-B2 | Aryloxy and arylalkyleneoxy substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-09-11 | — | — | US | disclosed |
| US-20110144099-A1 | ARYLOXY AND ARYLALKYLENEOXY SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY | 2011-06-16 | — | — | US | disclosed |
| US-7897597-B2 | Aryloxy and arylalkyleneoxy substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144099-A1 | ARYLOXY AND ARYLALKYLENEOXY SUBSTITUTED IMIDAZOQUINOLINES | IL2, IFNG, IRF3 | MAPT 4760/4885TP53 231/4885SMN1; SMN2 3907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.